Clinical Trials Browser

Phase 2 × Withdrawn × ipatasertib × Clear all

NCT04561817 2020-10-06

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Withdrawn

Ovarian Neoplasms, Recurrence